Anaplastic Thyroid Cancer: Current Concepts

  • Sylvie Galindo
  • Sam M. Wiseman
Part of the Head and Neck Cancer Clinics book series (HNCC)


Anaplastic thyroid cancer (ATC) is a rare and aggressive malignancy with an extremely poor prognosis compared to other types of thyroid cancer. Survival rates for ATC are dependent on the extent of disease at diagnosis, and many patients present with locally advanced or metastatic disease. Strong evidence suggests that ATC develops from pre-existing differentiated thyroid cancer (DTC) through a post-malignant cancer progression or anaplastic transformation. Current treatments are multimodal and offer little hope for a cure. Unfortunately, ATC has remained a highly lethal malignancy. ATCs possess genetic and molecular derangements that could be targeted by novel therapies in the future.


Epidermal Growth Factor Receptor Thyroid Cancer Differentiate Thyroid Cancer Medullary Thyroid Cancer Anaplastic Thyroid Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Gilliland FD, Hunt WC, Morris DM, et al. Prognostic factors for thyroid carcinoma: a population-based study of 15,698 cases from the surveillance, epidemiology and end results (SEER) Program 1973−1991. Cancer. 1997;79:564.Google Scholar
  2. 2.
    Hundahl SA, Blake C, Cunningham MP, et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996. Cancer. 2000;89:202.PubMedCrossRefGoogle Scholar
  3. 3.
    Hundahl SA, Fleming ID, Fremgen AM, et al. A national cancer database report on 53,856 cases of thyroid carcinoma treated in the United States, 1985–1995. Cancer. 1998;83:2638–48.Google Scholar
  4. 4.
    Kitamura Y, Shimizu K, Nagahama M, et al. Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. J Clin Endocrinol Metab. 1999;84:4043.PubMedCrossRefGoogle Scholar
  5. 5.
    Kebebew E, Greenspan FS, Clark OH, et al. Anaplastic thyroid carcinoma treatment outcomes and prognostic factors. Cancer. 2005;103:1330.PubMedCrossRefGoogle Scholar
  6. 6.
    McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery. 2001;130:1028.PubMedCrossRefGoogle Scholar
  7. 7.
    Segerhammar I, Larsson C, Nilsson I, et al. Anaplastic carcinoma of the thyroid gland: treatment and outcome over 13 years at one institution. J Surg Oncol. 2012;106:981–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Besic N, Hocevar M, Zgajnar J, et al. Prognostic factors in anaplastic carcinoma of the thyroid—a multivariate survival analysis of 188 patients. Lagenbecks Arch Surg. 2005;390:203.Google Scholar
  9. 9.
    Davies L, Welch HG. Thyroid cancer survival in the United States observational data from 1973 to 2005. Arch Otolaryngol Head Neck Surg. 2010;136:440.PubMedCrossRefGoogle Scholar
  10. 10.
    Aschebrooke-Kilfoy B, Ward MH, Sabra MM, et al. Thyroid cancer incidence patterns in the United States by histologic type, 1992−2006. Thyroid. 2011;21:125.CrossRefGoogle Scholar
  11. 11.
    Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973−2002. JAMA. 2006;295:2164.PubMedCrossRefGoogle Scholar
  12. 12.
    Han JM, Kim WB, Kim TY, et al. Time trend in tumour size and characteristics of anaplastic thyroid carcinoma. Clin Endocrinol. 2012;77:459.CrossRefGoogle Scholar
  13. 13.
    Yau T, Lo CY, Epstein RJ, et al. Treatment outcomes in anaplastic thyroid carcinoma: survival improvement in young patients with localized disease treated by combination of surgery and radiotherapy. Ann Surg Oncol. 2008;15:2500.PubMedCrossRefGoogle Scholar
  14. 14.
    Sugitani I, Kasai N, Fujimoto Y, et al. Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World J Surg. 2001;25:617.PubMedCrossRefGoogle Scholar
  15. 15.
    Orita Y, Sugitani I, Amemiya T, et al. Prospective application of our novel prognostic index in the treatment of anaplastic thyroid carcinoma. Surgery. 2011;150:1212.PubMedCrossRefGoogle Scholar
  16. 16.
    Chen J, Tward JD, Shrieve DC, et al. Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma analysis of surveillance, epidemiology, and end results 1983−2002. Am J Clin Oncol. 2008;31:460.PubMedCrossRefGoogle Scholar
  17. 17.
    Smallridge RC. Approach to the patient with anaplastic thyroid carcinoma. J Clin Endocrinol Metab. 2012;97:2566.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Wiseman SM, Loree TR, Rigual NR, et al. Anaplastic transformation of thyroid cancer: review of clinical, pathologic, and molecular evidence provides new insights into disease biology and future therapy. Head Neck. 2003;25:662.PubMedCrossRefGoogle Scholar
  19. 19.
    Rodriguez JM, Pinero A, Ortiz S, et al. Clinical and histological differences in anaplastic thyroid carcinoma. Eur J Surg. 2000;166:34–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Wiseman SM, Loree TR, Hicks WL, et al. Anaplastic thyroid cancer evolved from papillary carcinoma. Arch Otolaryngol Head Neck Surg. 2003;129:96.PubMedCrossRefGoogle Scholar
  21. 21.
    Gauchotte G, Phillipe C, Lacomme S, et al. BRAF, p53, and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis. Pathology. 2011;43:447.PubMedCrossRefGoogle Scholar
  22. 22.
    Quiros RM, Ding HG, Gattuso P, et al. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer. 2005;103:2261.PubMedCrossRefGoogle Scholar
  23. 23.
    Wang H, Huang Y, Huang J, et al. Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma. Ann Surg Oncol. 2007;14:3011.PubMedCrossRefGoogle Scholar
  24. 24.
    Stoler DL, Nowak NJ, Matsui S, et al. Comparative genomic instabilities of thyroid and colon cancers. Arch Otolaryngol Head Neck Surg. 2007;133:457.PubMedCrossRefGoogle Scholar
  25. 25.
    Wiseman SM, Griffith OL, Deen S, et al. Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma. Arch Surg. 2007;42:717.CrossRefGoogle Scholar
  26. 26.
    Schiff BA, McMurphy AB, Jasser SA, et al. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res. 2004;10:8594.PubMedCrossRefGoogle Scholar
  27. 27.
    Gule MK, Chen Y, Sano D, et al. Targeted Therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model. Clin Cancer Res. 2011;17:2281.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Derbel O, Limem S, Segura-Ferlay C, et al. Results of combined treatment of anaplastic thyroid carcinoma (ATC). BMC Cancer. 2011;11:469.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Tennvall J, Lundell G, Wahlberg P, et al. Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer. 2002;86:1848.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    De Crevoisier R, Baudin E, Bachelot A, et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiation Oncology Biol Phys. 2004;60:1137.CrossRefGoogle Scholar
  31. 31.
    Foote RL, Molina JR, Kasperbauer JL, et al. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid. 2011;21:25.PubMedCrossRefGoogle Scholar
  32. 32.
    Higashiyama T, Ito Y, Hirokawa M, et al. Optimal surgical procedure for locally curative surgery in patients with anaplastic thyroid carcinoma: importance of preoperative ultrasonography. Endocr J. 2010;57:763.PubMedCrossRefGoogle Scholar
  33. 33.
    Sugino K, Ito K, Mimura T, et al. The important role of operations in the management of anaplastic thyroid carcinoma. Surgery. 2002;131:245.PubMedCrossRefGoogle Scholar
  34. 34.
    Lang BH, Lo C. Surgical options in undifferentiated thyroid carcinoma. World J Surg. 2007;31:969.PubMedCrossRefGoogle Scholar
  35. 35.
    Pierie JEN, Muzikansky A, Randall MA, et al. The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol. 2002;9:57.PubMedCrossRefGoogle Scholar
  36. 36.
    Holting T, Meybier H, Buhr H. Status of tracheotomy in treatment of the respiratory emergency in anaplastic thyroid cancer. Wien Klin Wochenschr. 1990;102:264–6.PubMedGoogle Scholar
  37. 37.
    Bhatia A, Rao A, Ang K, et al. Anaplastic thyroid cancer: clinical outcomes with conformal radiotherapy. Head Neck. 2010;32:829.PubMedGoogle Scholar
  38. 38.
    Troch M, Koperek O, Sheuba C, et al. High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel. J Clin Endocrinol Metab. 2010;95:E54.PubMedCrossRefGoogle Scholar
  39. 39.
    Higashiyama T, Ito Y, Hirokawa M, et al. Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid. 2010;20:7.PubMedCrossRefGoogle Scholar
  40. 40.
    Kurebayashi J, Okubo S, Yamamoto Y, et al. Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells. Cancer Chemother Pharmacol. 2006;58:460.PubMedCrossRefGoogle Scholar
  41. 41.
    Podtcheko A, Ohtsuro A, Namba H, et al. Inhibition of ABL tyrosine kinase potentiates radiation-induced terminal growth arrest in anaplastic thyroid cancer cells. Radiat Res. 2006;165:35–42.PubMedCrossRefGoogle Scholar
  42. 42.
    Kim E, Matsuse M, Saenko V, et al. Imatinib enhances docetaxel-induced apoptosis through inhibition of nuclear factor-kB activation in anaplastic thyroid carcinoma cells. Thyroid. 2012;22:717–24.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Ha H, Lee J, Urba S, et al. A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid. 2010;20:975.PubMedCrossRefGoogle Scholar
  44. 44.
    Bible K, Suman V, Menefee M, et al. A multi-institutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab. 2012;97:1379.Google Scholar
  45. 45.
    Yu X, Phan T, Patel PN, et al. Chrysin activates notch1 signaling and suppresses tumor growth of anaplastic thyroid carcinoma in vitro and in vivo. Cancer. 2013;119:774–81.PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    Lin S, Yu Z, Riedl C, et al. Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus. Surgery. 2007;142:976.PubMedCrossRefGoogle Scholar
  47. 47.
    Alfano RW, Leppla SH, Liu S, et al. Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma. Mol Cancer Ther. 2010;9:190–201.PubMedCentralPubMedCrossRefGoogle Scholar
  48. 48.
    Kojic SL, Strugnell SS, Wiseman SM. Anaplastic thyroid cancer: a comprehensive review of novel therapy. Expert Rev Anticancer Ther. 2011;11:387.PubMedCrossRefGoogle Scholar

Copyright information

© K. Alok Pathak, Richard W. Nason, Janice L. Pasieka, Rehan Kazi, Raghav C. Dwivedi 2015

Authors and Affiliations

  1. 1.Department of SurgerySt. Paul’s Hospital & University of British ColumbiaVancouverCanada

Personalised recommendations